semaglutide april Weight-loss drugs are becoming more accessible, but are they always safe? Experts raise concerns about the misuse of generics and the risks of unsupervised use. From side effects to long-term impact Semaglutide slows epigenetic aging in

Our meals are created by chefs in consultation with nutrition professionals to align with the needs of those using GLP-1 medications

Pelvic floor physical therapy (PT) can make a big difference

Special attention is given to how dietary interventions may help mitigate common adverse events (AEs) associated with semaglutide, such as GI discomfort, and how specific macronutrient distributions, caloric targets, and meal patterns may enhance adherence, optimise therapeutic outcomes, and support favourable change in BC

In a phase 2, randomized, double-blind, placebo-controlled trial (NCT04881760) involving adults with obesity without type 2 diabetes, retatrutide (1 mg12 mg weekly) produced dose-dependent weight loss of up to 24.2% from baseline at 48 weeks, compared with 2.1% with placebo